Sanofi
Search results
Shantha Biotechnics Limited is an Indian biotechnology company headquartered in Hyderabad, India. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India.
H.No.5-10-173, 3rd & 4th Floors, Vasantha Chambers, Fateh Maidan Road, Basheerbagh, Hyderabad – 500 004. A.P., INDIA. Phone: +91 40 23234136. Fax: +91 40 23234103. E-mail: info@shanthabiotech.co.in.
A pioneer in the field of biotechnology, Shantha Biotechnics is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India. We are committed to breaking new ground in modern biotechnology to address critical healthcare needs of the developing world.
Shantha is equipped with state-of-the-art R&D facility, ideally designed for development of biologics, based on modern biotechnology. The facility has 50,000 sq.ft of laboratory area, divided in four independent laboratories.
Apr 20, 2011 · Founded by Dr. K.I. Varaprasad Reddy in 1993, Shantha was one of the first Indian biotechs to create a recombinant product, obtaining World Health Organization (WHO) prequalification for its Hepatitis B vaccine in 2002 [ 7 ]. Since then, the firm has grown to 750 employees and brought 11 novel products to market.
Manager -Regulatory Afffairs- SP Accure Labs. Shantha Biotechnics - India | 395 followers on LinkedIn.
Shantha Biotechnics Limited,Part of Sanofi Aventis Group | 7,730 followers on LinkedIn. A legend in vaccines.
Hyderabad, 5 July 2017: Shantha Biotechnics, the Hyderabad based affiliate of Sanofi Pasteur (the vaccines division of Sanofi), announced today its milestone achievement of having delivered 10 million doses of its cholera vaccine, ShancholTM.
May 13, 2012 · Two years after surrendering a $340-million supply contract, there is a glimmer of hope for ailing vaccine maker Shantha Biotech.
Jul 30, 2009 · The transaction gives Sanofi Pasteur a majority stake in vaccine producer Shantha Biotechnics (Hyderabad, India). The deal values Shantha at EUR 550 million ($778 million) and is expected to close before the end of the third quarter.
